Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma, Japan.
Mini Rev Med Chem. 2010 Jan;10(1):20-31. doi: 10.2174/138955710791112613.
Many therapeutic reagents for hepatitis B virus infection have established efficacy in goals such as alanine aminotransferase normalization, hepatitis B virus DNA suppression, HBeAg seroconversion, histological improvement, and reduce disease progression. However, it is not established that the efficacy of these reagents for the long-term survival and prevention of hepatocellular carcinoma although recent meta-analyses have also shown antiviral therapy to be efficacious. This article reviews the current status and innovative new options for antiviral therapy for hepatitis B and also discusses the various mechanisms of action for each drug, the results of clinical studies for each therapy, and the problems yet to be solved with respect to hepatitis B treatment.
许多乙型肝炎病毒感染的治疗试剂在丙氨酸氨基转移酶正常化、乙型肝炎病毒 DNA 抑制、HBeAg 血清学转换、组织学改善和减少疾病进展等目标方面已确立疗效。然而,这些试剂在长期生存和预防肝细胞癌方面的疗效尚未确定,尽管最近的荟萃分析也表明抗病毒治疗是有效的。本文综述了乙型肝炎抗病毒治疗的现状和创新新选择,讨论了每种药物的作用机制、每种治疗的临床研究结果以及乙型肝炎治疗中尚未解决的问题。